New antibody therapy stopped tumor growth and blocked spread in treatment-resistant triple-negative breast cancer models.

A newly engineered antibody can penetrate kidney cysts and interrupt the growth signals that drive polycystic kidney disease.

Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

After the government’s endorsement, many parents rushed to get their hands on leucovorin. They soon discovered that they were ...

The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of ...

Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.

The bispecific antibodies market offers promising opportunities due to its rising application in personalized medicine for cancers and autoimmune disorders, with significant growth in hematological ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and ...

A research team that includes Andrew Zydney, Bayard D. Kunkle Chair and professor of chemical engineering at Penn State, and ...